Protein Degraders Hit Their Stride
After years of breathless promises about intractable targets finally becoming druggable, protein degraders are starting to deliver – except perhaps not quite in the way many in the biotech world expected.

Through the glass window in Italy
This weekend’s EHA meeting revealed several different classes of protein degraders are indeed showing impressive clinical activity.
In some cases they’re also uncovering unexpected resistance mechanisms, which could threaten to make some opportunities obsolete faster than the companies developing them might care to admit!
Curious to learn more from our latest conference report?
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers